| Literature DB >> 33344804 |
Jie Zhang1, Zhongtao Liu1, Shujing Zhou1, Yang Teng1, Xiangyu Zhang1, Jinjing Li1.
Abstract
Based on the targeting of <span class="Chemical">ferroferric oxide (<span class="Chemical">Fe3O4) and the drug-loading property of <span class="Chemical">carbon nanotubes (CNTs), a novel <span class="Chemical">Span-PEG-composited Fe3O4-CNTs-DOX multifunctional ultrasound contrast agent was designed and applied to <span class="Disease">tumor lesions. In situ liquid phase synthesis was employed to prepare the <span class="Chemical">Fe3O4-CNTs magnetic targeting complex, and the physical method was used to obtain the <span class="Chemical">Fe3O4-CNTs-DOX complex by loading <span class="Chemical">doxorubicin (DOX) onto <span class="Chemical">Fe3O4-CNTs. The targeted drug-loading complex <span class="Chemical">Fe3O4-CNTs-DOX was combined with the membrane material of <span class="Chemical">Span-PEG by the acoustic vibration cavitation method. The maximum tolerance for <span class="Chemical">Span-PEG-composited Fe3O4-CNTs-DOX microbubbles was 450 times higher, which has good safety. The loading rate of DOX in the obtained composite microbubbles was 17.02%. The proliferation inhibition rate of <span class="Chemical">Span-PEG-composited Fe3O4-CNTs-DOX microbubbles on <span class="Disease">liver cancer <span class="CellLine">SMMC-7721 cells reached 48.3%. <span class="Chemical">Span-PEG-composited Fe3O4-CNTs-DOX microbubbles could significantly enhance ultrasonic imaging and enrich at a specific location under an external magnetic field, and the extended imaging time could ensure the effective observation and diagnosis of lesions.Entities:
Year: 2020 PMID: 33344804 PMCID: PMC7745219 DOI: 10.1021/acsomega.0c03325
Source DB: PubMed Journal: ACS Omega ISSN: 2470-1343
Figure 1XRD of the Fe3O4–CNTs complex (a), Fe3O4 (b), and CNTs (c).
Figure 2SEM of the Fe3O4–CNTs magnetic targeting complex.
Figure 3Hysteresis curve of the Span-PEG-composited Fe3O4–CNTs microbubble at room temperature.
Figure 4SEM (a), TEM (b), and structure simulation diagram (c) of Span-PEG-composited Fe3O4–CNTs microbubbles.[19,20]
Figure 5Size distribution of the Span-PEG-composited Fe3O4–CNTs microbubble.
Acute Toxicity of Span-PEG-Composited Fe3O4–CNTs Microbubble on Mice
| no. | mice type | gender | dose (mg·kg–1) | observation time (days) | acute toxicity |
|---|---|---|---|---|---|
| 1 | KM | male | 4500 | 14 | no |
| 2 | KM | male | 4500 | 14 | no |
| 3 | KM | male | 4500 | 14 | no |
| 4 | KM | male | 4500 | 14 | no |
| 5 | KM | male | 4500 | 14 | no |
| 6 | KM | male | 4500 | 14 | no |
| 7 | KM | male | 4500 | 14 | no |
| 8 | KM | male | 4500 | 14 | no |
| 9 | KM | male | 4500 | 14 | no |
| 10 | KM | male | 4500 | 14 | no |
| 11 | KM | male | 4500 | 14 | no |
| 12 | KM | male | 4500 | 14 | no |
| 13 | KM | male | 4500 | 14 | no |
| 14 | KM | male | 4500 | 14 | no |
| 15 | KM | male | 4500 | 14 | no |
| 16 | KM | male | 4500 | 14 | no |
| 17 | KM | male | 4500 | 14 | no |
| 18 | KM | male | 4500 | 14 | no |
| 19 | KM | male | 4500 | 14 | no |
| 20 | KM | male | 4500 | 14 | no |
Figure 6Muscle tissue sections of injection sites of mice: (a) control group and dose groups of (b) 2 days, (c) 4 days, (d) 10 days, (e) 22 days, and (f) 30 days.
Figure 7Inhibitory effect of Span-PEG-composited Fe3O4–CNTs–DOX microbubbles on Hepatoma SMMC-7721 cells.
Figure 8Cytotoxic effects of (a) Span-PEG microbubbles, (b) Span-PEG-composited CNT microbubbles, (c) Span-PEG-composited Fe3O4–CNTs microbubbles, (d) Span-PEG-composited CNTs–DOX microbubbles, (e) Span-PEG-composited Fe3O4–CNTs–DOX microbubbles, and (f) free DOX.
Figure 9AO/EB staining of hepatoma SMMC-7721 cells: (a) no treatment control group, (b) Span-PEG microbubble group, (c) Span-PEG-composited CNT microbubbles, (d) Span-PEG-composited Fe3O4–CNT microbubbles, (e) Span-PEG-composited CNTs–DOX microbubbles, (f) Span-PEG-composited Fe3O4–CNTs–DOX microbubbles, and (g) free DOX group.
Figure 10AO/EB staining of mouse fibroblast cells 3T3 of each administration group: (a) no treatment control group, (b) Span-PEG microbubble group, (c) Span-PEG-composited CNTs microbubble, (d) Span-PEG-composited Fe3O4–CNT microbubble, (e) Span-PEG-composited CNTs–DOX microbubble, (f) Span-composited Fe3O4–CNTs–DOX microbubble, and (g) the free DOX group.
Figure 11Ultrasonic imaging effect of rabbit kidney after injection of different contrast agents: (a) saline, (b) Span-PEG microbubble, (c) Span-PEG-composited CNT microbubble, and (d) Span-PEG-composited Fe3O4–CNTs–DOX microbubble.
Figure 12Ultrasonic imaging effect of rabbit liver after injection of different contrast agents: (a) saline, (b) Span-PEG microbubble, (c) Span-PEG-composited CNT microbubble, and (d) Span-PEG-composited Fe3O4–CNTs–DOX microbubble.
Figure 13Ultrasonic imaging effect of rabbit heart after injection of different contrast agents: (a) saline, (b) Span-PEG microbubble, (c) Span-PEG-composited CNT microbubble, and (d) Span-PEG-composited Fe3O4–CNTs–DOX microbubble.
Figure 14Ultrasound imaging of rabbit kidney (a), liver (b), and heart (c) after the injection of Span-PEG composite Fe3O4–CNTs–DOX microbubble under the magnetic field.